- Business Wire•22 minutes ago
Pfizer Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending that TRUMENBA® be granted marketing authorization in the European Union for active immunization of individuals 10 years and older to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B .3 The CHMP’s opinion will now ...
- Investopedia•5 hours ago
Bavencio, the first and only approved drug for MCC treatment, is under study for multiple other cancers.
- Bloomberg•7 hours ago
Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO ...
PFE : Summary for Pfizer, Inc. - Yahoo Finance
Pfizer Inc. (PFE)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||34.21 x 1000|
|Ask||34.49 x 400|
|Day's Range||34.07 - 34.27|
|52 Week Range||29.41 - 37.39|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||29.05|
|Dividend & Yield||1.28 (3.71%)|
|1y Target Est||N/A|